Research Progress of Antibody-targeted Immunoagonistic Drugs in Tumor Immunotherapy
Immune cell function is regulated by co-inhibitory and costimulatory receptors.Although immune checkpoint inhibitors are widely utilized in tumor therapy,their efficacy is hampered by the immunosuppressive tumor microenvironment.Immunoagonistic drugs,such as agonistic antibodies or their corresponding ligands targeting costimulatory receptors,have the potential to enhance the immune system's anti-tumor response and are emerging as a new generation of cancer treatment strategies.This review aims to introduce various types of immunoagonistic drugs developed in recent years and to evaluate the research progress of antibody-targeted immunoagonistic drugs in the field of tumor immunotherapy,in order to provide new insights for the development of the next generation of immunoagonistic drugs.
NETL
NSTL
万方数据
